These tumor-infiltrating B cells acquired PD-L1 expression and TGF-β competency which contributed to an immunosuppressive phenotype characterized by an enhanced inhibitory capacity against CD4+CD25− T cells, CD8+ T cells, and CD49b+NK cells, as well as promotion of Treg expansion (92). The gene discussed is CD4; the disease is neoplasm.